[{"id":"eaacbaad-f813-44b5-b98c-4ef8fd4a5156","acronym":"","url":"https://clinicaltrials.gov/study/NCT07480863","created_at":"2026-03-28T01:39:30.077Z","updated_at":"2026-03-28T01:39:30.077Z","phase":"Phase 2","brief_title":"Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL","source_id_and_acronym":"NCT07480863","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • vincristine • Inokai (orelabrutinib) • Anruixi (zuberitamab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/02/2029","study_completion_date":" 10/02/2029","last_update_posted":"2026-03-18"},{"id":"78b1d8da-ee62-4e5e-a188-4a012d565c96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863402","created_at":"2025-07-19T13:20:16.362Z","updated_at":"2025-07-19T13:20:16.362Z","phase":"Phase 2","brief_title":"Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype","source_id_and_acronym":"NCT06863402","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • nemtabrutinib (MK-1026)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/01/2029","primary_completion_date":" 04/01/2029","study_txt":" Completion: 04/01/2030","study_completion_date":" 04/01/2030","last_update_posted":"2025-07-18"},{"id":"2698d9cc-7b84-4f76-aa1a-1e9120402516","acronym":"MAVRiC","url":"https://clinicaltrials.gov/study/NCT07024706","created_at":"2025-06-21T13:19:49.221Z","updated_at":"2025-06-21T13:19:49.221Z","phase":"Phase 2","brief_title":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","source_id_and_acronym":"NCT07024706 - MAVRiC","lead_sponsor":"AstraZeneca","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 11/30/2032","primary_completion_date":" 11/30/2032","study_txt":" Completion: 11/30/2032","study_completion_date":" 11/30/2032","last_update_posted":"2025-06-17"},{"id":"60497dbb-56e8-4c40-973c-67ee89c74186","acronym":"","url":"https://clinicaltrials.gov/study/NCT06890585","created_at":"2025-09-07T02:05:51.287Z","updated_at":"2025-09-07T02:05:51.287Z","phase":"Phase 2","brief_title":"Zanubrutinib, Chidamide, and Rituximab Induction with or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL","source_id_and_acronym":"NCT06890585","lead_sponsor":"Li Zhiming","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • Epidaza (chidamide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-03-24"},{"id":"6496b67a-0445-408d-84b5-b4ec4d9b149e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06846463","created_at":"2025-03-03T10:04:54.767Z","updated_at":"2025-03-03T10:04:54.767Z","phase":"Phase 2","brief_title":"Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","source_id_and_acronym":"NCT06846463","lead_sponsor":"Virginia Commonwealth University","biomarkers":" BCL2 • NOTCH1 • MYD88 • CD79B • CD5","pipe":"","alterations":" ","tags":["BCL2 • NOTCH1 • MYD88 • CD79B • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 07/31/2029","primary_completion_date":" 07/31/2029","study_txt":" Completion: 07/31/2032","study_completion_date":" 07/31/2032","last_update_posted":"2025-02-26"},{"id":"3272fb35-7910-45fd-a4ab-4ef1f176f237","acronym":"BGB-3111-218","url":"https://clinicaltrials.gov/study/NCT05068440","created_at":"2021-10-05T20:00:21.125Z","updated_at":"2025-02-25T12:38:01.088Z","phase":"Phase 2","brief_title":"Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib","source_id_and_acronym":"NCT05068440 - BGB-3111-218","lead_sponsor":"BeiGene","biomarkers":" CD79B","pipe":" | ","alterations":" CD79B mutation • CD79B mutation","tags":["CD79B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B mutation • CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 08/11/2021","start_date":" 08/11/2021","primary_txt":" Primary completion: 10/21/2025","primary_completion_date":" 10/21/2025","study_txt":" Completion: 10/21/2025","study_completion_date":" 10/21/2025","last_update_posted":"2025-02-24"},{"id":"7d526185-7f46-4c4c-8f3a-7efa8cb4410a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03516617","created_at":"2021-01-18T17:18:31.951Z","updated_at":"2025-02-25T12:26:55.184Z","phase":"Phase 2","brief_title":"Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT03516617","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 03/15/2030","primary_completion_date":" 03/15/2030","study_txt":" Completion: 03/15/2031","study_completion_date":" 03/15/2031","last_update_posted":"2025-02-24"},{"id":"68f3baae-dc4f-43a6-80f0-573ab27bebb5","acronym":"ViPOR","url":"https://clinicaltrials.gov/study/NCT03223610","created_at":"2021-01-18T15:54:35.735Z","updated_at":"2025-02-25T13:39:32.188Z","phase":"Phase 1/2","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT03223610 - ViPOR","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 02/09/2018","start_date":" 02/09/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"7d8868d0-7506-42fd-b3db-474559dd352d","acronym":"19-C-0116","url":"https://clinicaltrials.gov/study/NCT04002947","created_at":"2021-01-18T19:40:23.873Z","updated_at":"2025-02-25T13:39:52.977Z","phase":"Phase 2","brief_title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04002947 - 19-C-0116","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 08/05/2019","start_date":" 08/05/2019","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 03/31/2030","study_completion_date":" 03/31/2030","last_update_posted":"2025-02-21"},{"id":"e2ff7fb5-f1de-4b7f-9fd4-438675875b61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02160015","created_at":"2021-01-18T10:03:19.018Z","updated_at":"2025-02-25T13:52:04.076Z","phase":"Phase 1","brief_title":"Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02160015","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 03/27/2017","primary_completion_date":" 03/27/2017","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-20"},{"id":"85055237-577b-4c03-b564-e7f118cc30e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06637501","created_at":"2025-02-25T14:11:41.845Z","updated_at":"2025-02-25T14:11:41.845Z","phase":"Phase 2","brief_title":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT06637501","lead_sponsor":"BeiGene","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)"],"overall_status":"Recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 11/14/2024","start_date":" 11/14/2024","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2025-02-19"},{"id":"c70f6861-a666-4861-ad3d-2301e394ab62","acronym":"ASCEND","url":"https://clinicaltrials.gov/study/NCT02970318","created_at":"2021-01-17T17:36:01.594Z","updated_at":"2025-02-25T14:01:11.516Z","phase":"Phase 3","brief_title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","source_id_and_acronym":"NCT02970318 - ASCEND","lead_sponsor":"Acerta Pharma BV","biomarkers":" CD5 • FCER2","pipe":" | ","alterations":" CD20 positive","tags":["CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib) • Zydelig (idelalisib) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 02/02/2017","start_date":" 02/02/2017","primary_txt":" Primary completion: 09/03/2021","primary_completion_date":" 09/03/2021","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-19"},{"id":"d69d9e8b-481b-4b6a-a241-66952601f3da","acronym":"RITZ","url":"https://clinicaltrials.gov/study/NCT05735834","created_at":"2023-02-21T16:01:53.200Z","updated_at":"2025-02-25T14:03:19.754Z","phase":"Phase 3","brief_title":"Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients","source_id_and_acronym":"NCT05735834 - RITZ","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/21/2024","start_date":" 05/21/2024","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-19"},{"id":"be1f4791-7f5f-42b3-86ee-a6bfee99acee","acronym":"ASSURE","url":"https://clinicaltrials.gov/study/NCT04008706","created_at":"2021-01-18T19:41:49.844Z","updated_at":"2025-02-25T14:07:28.508Z","phase":"Phase 3","brief_title":"Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients","source_id_and_acronym":"NCT04008706 - ASSURE","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • CD20 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • IGH mutation","tags":["TP53 • CD20 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 552","initiation":"Initiation: 09/17/2019","start_date":" 09/17/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-17"},{"id":"113cfda4-7d09-419b-a619-1fc822fa3cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03088878","created_at":"2021-01-18T15:13:07.925Z","updated_at":"2025-02-25T15:17:25.790Z","phase":"Phase 1/2","brief_title":"A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies","source_id_and_acronym":"NCT03088878","lead_sponsor":"Oncternal Therapeutics, Inc","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • zilovertamab (UC-961)"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 01/03/2018","start_date":" 01/03/2018","primary_txt":" Primary completion: 09/25/2024","primary_completion_date":" 09/25/2024","study_txt":" Completion: 09/25/2024","study_completion_date":" 09/25/2024","last_update_posted":"2025-02-12"},{"id":"82e136f4-d38a-459f-8a3f-411cfccafc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495464","created_at":"2022-08-10T12:55:30.197Z","updated_at":"2025-02-25T15:00:33.482Z","phase":"Phase 1","brief_title":"A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients with Previously Untreated High-risk Mantle Cell Lymphoma","source_id_and_acronym":"NCT05495464","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5","pipe":" | ","alterations":" CD20 positive • Chr t(11;14)","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-12"},{"id":"8e3b627a-4aef-4d49-a1cb-f09137cdb6c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06536049","created_at":"2025-02-25T15:21:55.068Z","updated_at":"2025-02-25T15:21:55.068Z","phase":"Phase 1/2","brief_title":"Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT06536049","lead_sponsor":"Yazeed Sawalha","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Epkinly (epcoritamab-bysp)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-12"},{"id":"814f07a4-6ae3-424e-b8de-ef7b7143e4c7","acronym":"BELLWAVE-010","url":"https://clinicaltrials.gov/study/NCT05947851","created_at":"2023-07-17T14:08:45.600Z","updated_at":"2025-02-25T15:28:11.395Z","phase":"Phase 3","brief_title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","source_id_and_acronym":"NCT05947851 - BELLWAVE-010","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53 • BTK • IGH","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53 • BTK • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • nemtabrutinib (MK-1026)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 08/08/2023","start_date":" 08/08/2023","primary_txt":" Primary completion: 06/27/2033","primary_completion_date":" 06/27/2033","study_txt":" Completion: 06/27/2033","study_completion_date":" 06/27/2033","last_update_posted":"2025-02-11"},{"id":"825e707d-d24d-4a05-b786-1228f5cc02ad","acronym":"Window-2","url":"https://clinicaltrials.gov/study/NCT03710772","created_at":"2021-01-18T18:11:30.804Z","updated_at":"2025-02-25T15:34:12.058Z","phase":"Phase 2","brief_title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT03710772 - Window-2","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • NSD2","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • CD20 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 05/22/2025","primary_completion_date":" 05/22/2025","study_txt":" Completion: 05/22/2025","study_completion_date":" 05/22/2025","last_update_posted":"2025-02-11"},{"id":"a65eaf0b-f986-4662-a858-795fc0730939","acronym":"","url":"https://clinicaltrials.gov/study/NCT04273139","created_at":"2021-01-18T20:45:24.651Z","updated_at":"2025-02-25T15:43:52.361Z","phase":"Phase 2","brief_title":"Ibrutinib + Venetoclax in Untreated WM","source_id_and_acronym":"NCT04273139","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • MYD88","pipe":" | ","alterations":" MYD88 mutation","tags":["BCL2 • MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/09/2020","start_date":" 07/09/2020","primary_txt":" Primary completion: 06/06/2022","primary_completion_date":" 06/06/2022","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-02-11"},{"id":"256f83da-7b60-4240-9f0a-ab88796e2617","acronym":"","url":"https://clinicaltrials.gov/study/NCT06649812","created_at":"2025-02-25T15:37:38.396Z","updated_at":"2025-02-25T15:37:38.396Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","source_id_and_acronym":"NCT06649812","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-02-10"},{"id":"53b3407a-20b5-4273-98e0-b8684d9dff01","acronym":"","url":"https://clinicaltrials.gov/study/NCT01829568","created_at":"2021-01-18T08:08:01.489Z","updated_at":"2025-02-25T14:34:07.166Z","phase":"Phase 1","brief_title":"Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma","source_id_and_acronym":"NCT01829568","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 06/26/2013","start_date":" 06/26/2013","primary_txt":" Primary completion: 05/11/2015","primary_completion_date":" 05/11/2015","study_txt":" Completion: 01/24/2026","study_completion_date":" 01/24/2026","last_update_posted":"2025-02-10"},{"id":"6d960e71-ed2a-4ebb-b9a5-92e7b593b1dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02629809","created_at":"2021-01-18T12:47:12.967Z","updated_at":"2025-02-25T15:25:24.207Z","phase":"Phase 2","brief_title":"Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT02629809","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/18/2016","start_date":" 03/18/2016","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-10"},{"id":"7aa05467-0129-42a5-a27e-e92acdec8860","acronym":"","url":"https://clinicaltrials.gov/study/NCT03701282","created_at":"2021-01-18T18:08:23.751Z","updated_at":"2025-02-25T15:43:14.904Z","phase":"Phase 3","brief_title":"Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT03701282","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 05/07/2028","primary_completion_date":" 05/07/2028","study_txt":" Completion: 05/07/2028","study_completion_date":" 05/07/2028","last_update_posted":"2025-02-10"}]